Previously at MeiraGTx, GSK and Novartis, Dr. Leighton will help Chemify scale the company’s operational capacity to meet ...
Business Wire
|
January 10, 2025
Leveraging Real Chemistry’s differentiated deep biopharma expertise and Corval’s cutting-edge commercialization planning platform, the collaboration aims to accelerate ...
October 2, 2024
Scientist.com hosts webinar series exploring the fundamentals of neural networks and the latest applications of large language models ...
July 30, 2024
Three new AI-powered products connect strategic priorities to the optimal tactic mix and resource allocation to drive higher ...
September 26, 2023
Tübingen, Germany-based CureVac, a biopharmaceutical company developing transformative medicines based on mRNA, announced on Tuesday, February 7, the ...
Editorial team
February 9, 2023
TargED Biopharmaceuticals, an Utrecht-based biotechnology company focused on developing improved treatments for thrombotic diseases, announced that it has ...
February 24, 2022
Angelini Pharma - part of the private Italian Angelini Group - has announced that it is looking to acquire Arvelle Therapeutics, a Swiss-based biopharmaceutical company
January 5, 2021
Building on years of innovation—from the Dante Labs Genome to the Avanti Platform—Dante Omics AI introduces fully integrated ...
February 5, 2025
On Monday, Copenhagen-based Enduro Genetics, a synthetic biology startup, announced that it has raised €12M in a Series ...
Vigneshwar Ravichandran
February 3, 2025
Primary endpoint met with statistical significance (p=0.027) in pivotal RELIVE trial of eyonis™ LCS, Median’s AI/ML-based Software as ...
H2 2024 revenue €12.0 million up 10.2% compared to H2 2023 FY 2024 revenue €22.9 million up 3.3% ...
January 31, 2025
Enterprise Ireland grant awarded to ICON to further enhance artificial intelligence capabilities DUBLIN–(BUSINESS WIRE)–ICON plc, (NASDAQ: ICLR) a ...
January 30, 2025
01
02
03
04
05
More
[wp_dark_mode style="2"]
01
From employee advocacy to social selling: Oktopost founder Daniel Kushner on the future of B2B marketing